Torrent Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Samir Mehta
Algemeen directeur
₹260.0m
Totale compensatie
| Percentage CEO-salaris | 0.02% |
| Dienstverband CEO | 35.8yrs |
| Eigendom CEO | 0.0002% |
| Management gemiddelde ambtstermijn | 2.3yrs |
| Gemiddelde ambtstermijn bestuur | 2.4yrs |
Recente managementupdates
Recent updates
Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts
Oct 29
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing
Oct 24Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Just Reported And Analysts Have Been Lifting Their Price Targets
Jul 26Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹18b |
| Jun 30 2024 | n/a | n/a | ₹17b |
| Mar 31 2024 | ₹260m | ₹40k | ₹17b |
| Dec 31 2023 | n/a | n/a | ₹15b |
| Sep 30 2023 | n/a | n/a | ₹13b |
| Jun 30 2023 | n/a | n/a | ₹13b |
| Mar 31 2023 | ₹230m | ₹40k | ₹12b |
| Dec 31 2022 | n/a | n/a | ₹8b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹200m | ₹40k | ₹8b |
| Dec 31 2021 | n/a | n/a | ₹12b |
| Sep 30 2021 | n/a | n/a | ₹13b |
| Jun 30 2021 | n/a | n/a | ₹13b |
| Mar 31 2021 | ₹200m | ₹40k | ₹13b |
| Dec 31 2020 | n/a | n/a | ₹12b |
| Sep 30 2020 | n/a | n/a | ₹12b |
| Jun 30 2020 | n/a | n/a | ₹11b |
| Mar 31 2020 | ₹200m | ₹40k | ₹10b |
| Dec 31 2019 | n/a | n/a | ₹6b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹5b |
| Mar 31 2019 | ₹150m | ₹40k | ₹4b |
| Dec 31 2018 | n/a | n/a | ₹8b |
| Sep 30 2018 | n/a | n/a | ₹6b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹150m | ₹40k | ₹7b |
Compensatie versus markt: De totale vergoeding ($USD 3.08M ) Samir } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 1.10M ).
Compensatie versus inkomsten: De vergoeding van Samir is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Samir Mehta (60 yo)
35.8yrs
Tenure
₹260,040,000
Compensatie
Mr. Samir Uttamlal Mehta, B.Com., MBA serves as a Managing Director of Torrent Pharmaceuticals Limited since 1989. Mr. Mehta served as Managing Director of Torrent Power Limited. Mr. Mehta has been associa...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman & MD | no data | ₹260.04m | 0.00024% ₹ 2.6m | |
| Whole-Time Director | 2.3yrs | ₹65.88m | 0.000060% ₹ 643.8k | |
| Chief Financial Officer | 6.2yrs | ₹16.30m | geen gegevens | |
| Company Secretary & Compliance Officer | 2.3yrs | geen gegevens | geen gegevens | |
| Vice President of Human Resource | no data | ₹6.56m | geen gegevens | |
| Executive Director | less than a year | ₹8.25m | geen gegevens | |
| Chief Customer Service Officer | 3.4yrs | geen gegevens | geen gegevens | |
| President and CEO of Torrent Pharma USA | no data | geen gegevens | geen gegevens |
2.3yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TORNTPHARM wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman & MD | 35.8yrs | ₹260.04m | 0.00024% ₹ 2.6m | |
| Whole-Time Director | 2.3yrs | ₹65.88m | 0.000060% ₹ 643.8k | |
| Executive Director | less than a year | ₹8.25m | geen gegevens | |
| Chairman Emeritus | 10.3yrs | geen gegevens | 0.00030% ₹ 3.2m | |
| Independent Director | 1.1yrs | ₹2.60m | geen gegevens | |
| Independent Director | 2.3yrs | ₹4.30m | geen gegevens | |
| Independent Director | 6.3yrs | ₹4.90m | 0.00050% ₹ 5.4m | |
| Independent Director | 5.7yrs | ₹6.70m | geen gegevens | |
| Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 2.5yrs | ₹6.30m | geen gegevens |
2.4yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TORNTPHARM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.